Dashboard/VERV/VERVE-102/event

InterimInterim Analysis

VERVE-102 Heart-2 Cohort 3 Data (HeFH)

VERV·VERVE-102·Familial Hypercholesterolemia·

Phase 2

·NCT05814822

current best date

'26

QTR6 months

Takeaway

Cohort 3 dose-escalation data for Verve’s in-vivo base-editing therapy targeting PCSK9 in heterozygous familial hypercholesterolemia (HeFH). Watch: PCSK9 protein knockdown %, LDL-C reduction, hepatic and immunogenicity safety events.

What’s at stake

market · comparables · base rate · prior moves

Market opportunity

—

company filings

Peer comparables

1 readout

ClinicalTrials.gov

Stage base rate

~14%

BIO Industry Analysis 2023 (2011–2020)

Avg prior-readout move

—

historical price reactions

MoALNP-delivered base editor targeting PCSK9

VERVE-102 is Verve Therapeutics' in vivo base-editing therapy designed to provide a one-time, permanent reduction in LDL cholesterol in patients with heterozygous familial hypercholesterolemia (HeFH) — a dominant genetic disorder affecting 1 in 250 people that causes severely elevated LDL from birth. A single IV infusion delivers an adenine base editor via lipid nanoparticles to liver cells, converting a single DNA letter in the PCSK9 gene to a permanent loss-of-function variant that prevents the liver from degrading LDL receptors. The goal is lasting LDL-C reduction from one infusion, as an alternative to lifelong statin therapy and bi-weekly PCSK9 inhibitor injections.

Indication

Cardio-Renal

Familial Hypercholesterolemia

MeSH · D006938

No primer in glossary yet.

Trial

active

NCT05814822 ↗

Heart-2 Phase 1b VERVE-102 in HeFH

Glossary · what this readout is measuring

2 terms detected in the takeaway

PCSK9target
Proprotein Convertase Subtilisin/Kexin type 9
Liver enzyme that degrades LDL receptors. Inhibiting it (mAbs, siRNA, base-editing) lowers LDL-C dramatically.
LDL-Cendpoint
Low-density lipoprotein cholesterol
"Bad" cholesterol. FcRn inhibitors are known to elevate LDL by 20-40%, which matters for chronic dosing in patients with cardiovascular risk.

Reference data · comparable readouts

How Ph2 readouts in Cardio-Renal have landed.

Reference, not prediction. We surface the historical record so you can read it yourself. We never extrapolate to the upcoming event.

Positive

0/0

0% in record

Primary endpoint hit

across 0 readouts

Drug · sponsorPhase · yearOutcomeKey metricSource

omecamtiv mecarbil

CYTK · HF

Ph3 · Oct 2022mixednarrow CV-death/HF benefit; FDA declinedFDA

finerenone (FIDELIO-DKD)

BAYRY · CKD

Ph3 · Jul 2020positive18% reduction in primary compositePR

sorted by phase match, then recency · sources span PR wires, CT.gov, FDA notices, and conference presentations · we never editorialize the outcome label

Competitive landscape

4 peers in Cardio-Renal · ranked by indication + modality match

Drug	Company	Modality	Mechanism	Next catalyst
AMVUTTRAvutrisiran	ALNY	siRNA	TTR-targeting RNAi	PDUFA · Dec 26
plozasiran	ARWR	siRNA	APOC3-targeting RNAi	CONFERENCE · May 26
olezarsen	IONS	oligonucleotide	ApoCIII antisense oligonucleotide	PDUFA · Dec 26
XPHOZAHtenapanor	ARDX	small molecule	NHE3 inhibitor	CMC · Jul 26

Disclosure trail

1 observation · sorted by confidence

Apr 15, 2026·15d agopinned · highest confidence
HIGH confPR
top claim
Q4'26
QTR
“VERVE-102 Heart-2 Cohort 3 dose-escalation data in patients with heterozygous familial hypercholesterolemia is expected in the fourth quarter of 2026.”
conf 85%via llm

MethodologyEvery catalyst date is anchored to a primary source. Disclosures with confidence ≥ 0.85 auto-publish; the rest are reviewed by a human within 24 hours. We never interpret data — we organize public information.